{"id":"https://openalex.org/W4387981049","doi":"https://doi.org/10.1183/13993003.congress-2023.pa3052","title":"Late Breaking Abstract - Validation of assays measuring functional alpha-1 antitrypsin (AAT) in patients with AAT deficiency (AATD)","display_name":"Late Breaking Abstract - Validation of assays measuring functional alpha-1 antitrypsin (AAT) in patients with AAT deficiency (AATD)","publication_year":2023,"publication_date":"2023-09-09","ids":{"openalex":"https://openalex.org/W4387981049","doi":"https://doi.org/10.1183/13993003.congress-2023.pa3052"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2023.pa3052","doi":"https://doi.org/10.1183/13993003.congress-2023.pa3052","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2023.pa3052","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5093133331","display_name":"Jason Zour","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Zour","raw_affiliation_strings":["Inhibrx, Inc., La Jolla, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, Inc., La Jolla, United States","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110931794","display_name":"Varun Ramani","orcid":"https://orcid.org/0009-0004-0196-4626","observed_orcids":["https://orcid.org/0009-0004-0196-4626"]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Varun Ramani","raw_affiliation_strings":["Inhibrx, Inc., La Jolla, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, Inc., La Jolla, United States","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Carolina Bellizzi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carolina Bellizzi","raw_affiliation_strings":["Inhibrx, Inc., La Jolla, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, Inc., La Jolla, United States","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017432951","display_name":"Buket Onel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Buket Onel","raw_affiliation_strings":["BioAgilytix Labs, Durham, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioAgilytix Labs, Durham, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093133332","display_name":"Liz Nolff","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Liz Nolff","raw_affiliation_strings":["BioAgilytix Labs, Durham, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioAgilytix Labs, Durham, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064638988","display_name":"Brendan P. Eckelman","orcid":"https://orcid.org/0009-0006-7090-2642","observed_orcids":["https://orcid.org/0009-0006-7090-2642"]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brendan Eckelman","raw_affiliation_strings":["Inhibrx, Inc., La Jolla, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, Inc., La Jolla, United States","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038102558","display_name":"Carson Veldstra","orcid":"https://orcid.org/0009-0001-2809-0234","observed_orcids":["https://orcid.org/0009-0001-2809-0234"]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carson Veldstra","raw_affiliation_strings":["Inhibrx, Inc., La Jolla, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, Inc., La Jolla, United States","institution_ids":["https://openalex.org/I4210126924"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA3052","last_page":"PA3052"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.24570000171661377,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.24570000171661377,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10620","display_name":"Protease and Inhibitor Mechanisms","score":0.12269999831914902,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.09229999780654907,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alpha-1-antitrypsin-deficiency","display_name":"alpha-1 antitrypsin deficiency","score":0.9980000257492065},{"id":"https://openalex.org/keywords/neutrophil-elastase","display_name":"neutrophil elastase","score":0.828000009059906},{"id":"https://openalex.org/keywords/bioanalytical-method-validation","display_name":"bioanalytical method validation","score":0.7480000257492065},{"id":"https://openalex.org/keywords/bronchoalveolar-lavage-fluid","display_name":"bronchoalveolar lavage fluid","score":0.9269999861717224},{"id":"https://openalex.org/keywords/augmentation-therapy","display_name":"augmentation therapy","score":0.7649999856948853},{"id":"https://openalex.org/keywords/enzyme-activity-assay","display_name":"enzyme activity assay","score":0.5389999747276306},{"id":"https://openalex.org/keywords/chromogenic-substrates","display_name":"chromogenic substrates","score":0.6169999837875366},{"id":"https://openalex.org/keywords/lung-disease","display_name":"lung disease","score":0.4090000092983246}],"concepts":[{"id":"https://openalex.org/C2777961210","wikidata":"https://www.wikidata.org/wiki/Q927148","display_name":"Bronchoalveolar lavage","level":3,"score":0.5802830457687378},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4144560396671295},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40934091806411743},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.38655877113342285},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3714474141597748},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30135342478752136},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.24879184365272522},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.218824565410614}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2023.pa3052","doi":"https://doi.org/10.1183/13993003.congress-2023.pa3052","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2023.pa3052","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4413023951","https://openalex.org/W7167784389","https://openalex.org/W2740859899","https://openalex.org/W6999747872","https://openalex.org/W7161547652","https://openalex.org/W3216782236","https://openalex.org/W3124082413","https://openalex.org/W4389895287","https://openalex.org/W4313178477","https://openalex.org/W7161549619"],"abstract_inverted_index":{"Introduction:":[0],"AAT":[1,18,33,40,68,162],"is":[2,14],"a":[3,65,76],"potent":[4],"inhibitor":[5],"of":[6,31,124,131,156,202,236],"neutrophil":[7],"elastase":[8],"(NE)":[9],"in":[10,43,108,120,164,205,224,242],"the":[11,139,199,217],"lungs.":[12],"AATD":[13,238],"associated":[15,220],"with":[16,56,221],"low":[17],"levels":[19,71],"and":[20,45,102,111,142,159,166,177,184,193,226],"increased":[21],"lung":[22],"disease":[23],"risk.":[24],"In":[25],"studies":[26],"that":[27],"informed":[28],"FDA":[29,140],"approval":[30],"plasma-derived":[32],"(pdAAT)":[34],"for":[35,91,99,170,232],"treating":[36],"AATD,":[37],"observed":[38],"functional":[39,66],"(fAAT)":[41],"increases":[42],"serum":[44,67,203],"bronchoalveolar":[46],"lavage":[47],"fluid":[48],"(BALF)":[49,192],"indicated":[50],"biochemical":[51,234],"efficacy.":[52],"However,":[53],"augmentation":[54],"therapy":[55],"pdAAT":[57],"targets":[58],"an":[59,88,116],"antigenic":[60],"(ie,":[61],"total)":[62],"rather":[63],"than":[64],"level.":[69],"fAAT":[70,93,106,125,158,204,223],"are":[72],"determined":[73,114],"by":[74,115],"measuring":[75,222],"sample\u2019s":[77],"anti-NE":[78],"capacity":[79],"(ANEC),":[80],"but":[81],"reproducibility":[82],"can":[83],"be":[84,209],"challenging.":[85],"We":[86,134],"developed":[87],"ANEC-based":[89],"method":[90,100,137,146],"quantifying":[92],"to":[94,126],"meet":[95],"regulatory":[96],"agency":[97],"expectations":[98],"validation":[101,147],"trial":[103],"use.":[104],"Methods:":[105],"concentrations":[107],"human":[109,161],"sera":[110,165],"BALF":[112,225],"were":[113,173,189],"enzymatic":[117],"ANEC":[118,154,214],"assay":[119,152,215],"which":[121],"irreversible":[122],"binding":[123],"NE":[127],"inhibits":[128],"NE-mediated":[129],"hydrolysis":[130],"chromogenic":[132],"MeOSuc-AAPV-pNA.":[133],"evaluated":[135],"our":[136],"using":[138],"2018":[141],"ICH":[143],"M10":[144],"bioanalytical":[145],"(BMV)":[148],"guidelines.":[149],"Results:":[150],"Our":[151],"detected":[153],"activity":[155],"endogenous":[157],"recombinant":[160],"INBRX-101":[163],"BALF.":[167],"Acceptance":[168],"criteria":[169],"BMV":[171],"parameters":[172],"met,":[174],"including":[175],"intra-":[176],"interassay":[178],"precision,":[179],"selectivity/matrix":[180],"interference,":[181],"dilution":[182],"linearity,":[183],"sample":[185],"stability.":[186],"Dynamic":[187],"ranges":[188],"14-56":[190],"nM":[191],"1-5.6":[194],"\u00b5M":[195],"(serum).":[196],"Data":[197],"on":[198],"normal":[200],"range":[201],"healthy":[206],"volunteers":[207],"will":[208],"presented.":[210],"Conclusions:":[211],"This":[212],"validated":[213],"addresses":[216],"unique":[218],"challenges":[219],"sera,":[227],"making":[228],"it":[229],"well":[230],"suited":[231],"evaluating":[233],"efficacy":[235],"novel":[237],"therapies":[239],"(eg,":[240],"INBRX-101)":[241],"registrational":[243],"clinical":[244],"trials.":[245]},"counts_by_year":[],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2023-10-28T00:00:00"}